Fundraising FoxThird Pole
Waltham, US · Founded 2014 · Delaware corporation · 2 known investors
Find your way into Third Pole
86 people in our graph share verified history with the Third Pole team — schools, employers, funds. One of them is your warm intro.
Cuinn Alexanderunlockedknows Bill Athenson · together at Third Pole Therapeutics (overlapped)
knows the team · via Third Pole Therapeutics
knows the team · via Nanosphere
×9knows the team · via Cardinal Health
Third Pole develops portable and miniaturized devices that generate inhaled nitric oxide on-demand for hospital and mobile treatment of severe cardiopulmonary diseases and lung infections. The company uses a patented technology inspired by natural lightning to produce nitric oxide safely and efficiently from air and electricity.
Founders & leadership
EH
Elizabeth HolmbergCFO and Treasurer
BA
Basil AthensonChief Executive Officer and President
BA
Bill AthensonChief Executive OfficerHe brings over 20 years of healthcare industry experience across pharma, life sciences, medical devices, and diagnostics, including prior roles at Fortune 15 companies and early-stage healthcare technology ventures.
GK
Gordon KinderChief Financial Officer
PS
Philip SilkoffChief Medical Officer
DZ
David ZapolNamed on SEC filing
Board
JM
WC
Werner CautreelsBoard director
RR
Ron RobisonBoard director
WH
William HeidenBoard director
HP
Hirak ParikhBoard director
AP
Ashleigh PalmerBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$85.8M disclosed across 3 rounds · 2015–2024
▶$16.9MraisedMar 2025 · 22 investors · Other TechnologyRule 506(b)
▶$16.9MraisedMar 2025 · 22 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Werner CautreelsDirector
- David ZapolDirector
- Emily Ladd-KravitzExecutive Officer
- Elizabeth HolmbergExecutive Officer
- Jeffrey McCormickDirector
- Ron RobisonDirector
- William HeidenDirector
- Hirak ParikhDirector
- Basil AthensonDirector, Executive Officer
- Offering amount
- $30M
- Amount sold
- $16.9M
- Placement agents
- Saturn Capital, Inc.
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$55.2MraisedFeb 2024 · 85 investors · Other TechnologyRule 506(b)
▶$55.2MraisedFeb 2024 · 85 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Basil AthensonDirector, Executive Officer
- Matthew GaylordDirector
- Emily Ladd-KravitzExecutive Officer
- Ron RobisonDirector
- Elizabeth HolmbergExecutive Officer
- Jeffrey McCormickDirector
- Werner CautreelsDirector
- William HeidenDirector
- Amount sold
- $55.2M
- Placement agents
- Saturn Capital, Inc.
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.8MraisedJan 2018 · 49 investors · Other TechnologyRule 506(b)
▶$13.8MraisedJan 2018 · 49 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Ashleigh PalmerDirector
- David ZapolExecutive Officer, Director, Promoter
- Jeffrey McCormickDirector
- Offering amount
- $14M
- Amount sold
- $13.8M
- Minimum investment
- $15K
- Sales commissions
- $1.1M
- Proceeds to insiders
- $426K
- Placement agents
- Saturn Capital, Inc.
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Third Pole do?
- Third Pole develops portable and miniaturized devices that generate inhaled nitric oxide on-demand for hospital and mobile treatment of severe cardiopulmonary diseases and lung infections. The company uses a patented technology inspired by natural lightning to produce nitric oxide safely and efficiently from air and electricity.
- Who are Third Pole's investors?
- Third Pole's investors include Saturn Partners, Unorthodox Ventures.
- How much funding has Third Pole raised?
- Third Pole has disclosed $85.8M raised across 3 rounds.
- Where is Third Pole headquartered?
- Third Pole is headquartered in Waltham, US.